NDATOPICALSPONGE
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PHARMASEAL SCRUB CARE (chlorhexidine gluconate) by Fusion Pharmaceuticals Inc. is clinical pharmacology periogard® (chlorhexidine gluconate oral rinse usp, 0. First approved in 1988.
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHARMASEAL SCRUB CARE is a topical chlorhexidine gluconate 0.12% oral rinse formulation delivered as a sponge for preoperative oral antisepsis and plaque reduction. It works through broad-spectrum antimicrobial activity, reducing aerobic and anaerobic oral bacteria by 54–97% with ~30% of active drug retained in the oral cavity for sustained release. Patients using this product are those undergoing oral surgical procedures or requiring antimicrobial oral care in hospital/clinical settings.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), suggesting a defensive/niche positioning focused on retention rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate oral rinse's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general…
Indications
Worked on PHARMASEAL SCRUB CARE at Fusion Pharmaceuticals Inc.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.